- Home
- MYSE vs TXMD Comparison
MYSE vs TXMD Comparison
Compare MYSE & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYSE
- TXMD
- Stock Information
- Founded
- MYSE 2014
- TXMD 2008
- Country
- MYSE United States
- TXMD United States
- Employees
- MYSE N/A
- TXMD N/A
- Industry
- MYSE Telecommunications Equipment
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- MYSE Telecommunications
- TXMD Health Care
- Exchange
- MYSE Nasdaq
- TXMD Nasdaq
- Market Cap
- MYSE 11.8M
- TXMD 12.3M
- IPO Year
- MYSE 2021
- TXMD N/A
- Fundamental
- Price
- MYSE $2.89
- TXMD $1.23
- Analyst Decision
- MYSE
- TXMD
- Analyst Count
- MYSE 0
- TXMD 0
- Target Price
- MYSE N/A
- TXMD N/A
- AVG Volume (30 Days)
- MYSE 253.5K
- TXMD 506.6K
- Earning Date
- MYSE 11-13-2025
- TXMD 11-12-2025
- Dividend Yield
- MYSE N/A
- TXMD N/A
- EPS Growth
- MYSE N/A
- TXMD N/A
- EPS
- MYSE N/A
- TXMD N/A
- Revenue
- MYSE $315.00
- TXMD $2,559,000.00
- Revenue This Year
- MYSE N/A
- TXMD $427.09
- Revenue Next Year
- MYSE N/A
- TXMD N/A
- P/E Ratio
- MYSE N/A
- TXMD N/A
- Revenue Growth
- MYSE N/A
- TXMD 156.93
- 52 Week Low
- MYSE $1.38
- TXMD $0.70
- 52 Week High
- MYSE $9.34
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- MYSE 55.33
- TXMD 59.44
- Support Level
- MYSE $2.56
- TXMD $1.20
- Resistance Level
- MYSE $3.00
- TXMD $1.37
- Average True Range (ATR)
- MYSE 0.26
- TXMD 0.12
- MACD
- MYSE -0.03
- TXMD 0.02
- Stochastic Oscillator
- MYSE 43.41
- TXMD 29.85
About MYSE Myseum Inc. Common Stock
Myseum Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.